[Immediate results of sarcolysine therapy of patients with malignant tumors of the ovaries]
Non-randomised trial
public-domain-us
AI-generated summary
Analysis of 41 ovarian cancer patients identified age, ascites, dual administration routes, high total dose, and surgical extent as factors influencing sarcolysin therapeutic efficacy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The data on 41 patients with epithelial malignant tumors of the ovaries, who received sarcolysin at different stages of combined treatment, were analyzed. The following factors of therapeutic effect of sarcolysin were established: age of 41-50 years, presence of ascites, administration by two routes--intravenously and intracavitarily and a total dose in excess of 160 mg. Still another factor is contributed by the extent of surgical procedure carried out as primary treatment.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-11T09:27:45.537177+00:00
- pubmed
- last seen: 2026-10-08T21:58:26.348914+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine